BIOMAT Database Logo BIOMAT Database Logo

Prevention of experimental Haemophilus ducreyi infection: a randomized, controlled clinical trial. 1998

A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Department of Medicine, Indiana University, Indianapolis, USA.

Human subjects were infected with Haemophilus ducreyi. All subjects developed papules and were randomized to treatment with a single dose of azithromycin (1 g) or ciprofloxacin (500 mg). At weekly intervals, volunteers were reinoculated with H. ducreyi, and drug concentrations were measured in peripheral blood mononuclear cells (PBMC). When papules developed, the subjects were treated with antibiotics and dismissed from the study. Eight of the ciprofloxacin-treated subjects developed papules 1 week after the initial treatment, and the ninth subject developed disease 2 weeks after treatment. The 9 azithromycin-treated subjects developed papules 4-10 weeks (mean, 6.8) after the initial treatment (P < .001). Azithromycin was detected in PBMC for 3-6 weeks (mean, 4). Pre- and posttreatment lesions had histology typical of experimental chancroid or were culture positive. Azithromycin prevents experimental chancroid for nearly 2 months. These findings have implications for strategies to prevent chancroid.

UI MeSH Term Description Entries
D008297 Male Males
D002602 Chancroid Acute, localized autoinoculable infectious disease usually acquired through sexual contact. Caused by HAEMOPHILUS DUCREYI, it occurs endemically almost worldwide, especially in tropical and subtropical countries and more commonly in seaports and urban areas than in rural areas.
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006191 Haemophilus ducreyi A species of HAEMOPHILUS that appears to be the pathogen or causative agent of the sexually transmitted disease, CHANCROID. Bacillus ulceris cancrosi,Coccobacillus ducreyi,Hemophilus ducreyi
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Experimental human infection with Haemophilus ducreyi.
May 1994, The Journal of infectious diseases,
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Oropharyngeal Haemophilus ducreyi infection.
September 1983, British medical journal (Clinical research ed.),
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Haemophilus ducreyi infection in Manchester.
July 1983, Lancet (London, England),
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Immunopathogenesis of Haemophilus ducreyi infection (chancroid).
April 2002, Infection and immunity,
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Swine model of Haemophilus ducreyi infection.
August 1995, Infection and immunity,
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience.
June 2009, The Journal of infectious diseases,
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Haemophilus ducreyi elicits a cutaneous infiltrate of CD4 cells during experimental human infection.
February 1996, The Journal of infectious diseases,
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Conjunctivitis due to Haemophilus ducreyi infection.
December 1980, The British journal of venereal diseases,
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Standardization of the experimental model of Haemophilus ducreyi infection in human subjects.
December 1998, The Journal of infectious diseases,
A C Thornton, and E M O'Mara, and S J Sorensen, and T J Hiltke, and K Fortney, and B Katz, and R E Shoup, and A F Hood, and S M Spinola
Pathophysiological concept of Haemophilus ducreyi infection (chancroid)
January 1992, International journal of STD & AIDS,
Copied contents to your clipboard!